Zydus Cadila has received the final approval from the U.S. Food & Drug Administration (USFDA) to market Desvenlafaxine Extended-Release Tablets, 50 mg and 100 mg. The drug is used to treat major depression and will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Total volume of shares traded on the bourses today was lower by 52.05% to 600,531 compared with 22-day average volume of 1,252,527.

Shares of the company gained Rs 8.65, or 1.76%, to trade at Rs 500.00. The total volume of shares traded was 34,356 at the BSE (12.58 p.m., Thursday).